CRRT Effluent Dose for Morbidly Obese Patients
For morbidly obese patients (BMI ≥40 kg/m²) requiring CRRT, prescribe an effluent dose of 35 mL/kg/hour using ideal body weight (IBW) for dose calculation, not actual body weight.
Dosing Strategy
The evidence strongly supports using IBW rather than actual body weight (ABW) or adjusted body weight (AdjBW) when calculating CRRT dose in obese patients. A 2023 retrospective study of 1,033 critically ill adults demonstrated that CRRT dose indexed to ABW or AdjBW predicted increased mortality (hazard ratio 1.2-1.16), while dosing based on IBW showed no such association (HR 1.04) 1. This finding is critical because it suggests that dosing based on actual weight in obese patients may lead to excessive treatment intensity and potentially harmful outcomes.
Target Effluent Rate
The baseline recommendation from the 2002 International Consensus Conference establishes that 35 mL/kg/hour of continuous venovenous hemofiltration (CVVH) is associated with improved survival compared to 20 mL/kg/hour in critically ill patients with ARF 2. This recommendation should be applied using IBW in morbidly obese patients.
Calculation Example:
- For a morbidly obese patient with IBW of 70 kg
- Target effluent: 35 mL/kg/hour × 70 kg = 2,450 mL/hour (approximately 2.5 L/hour)
- Do NOT use their actual weight of 150+ kg, which would result in dangerously high effluent rates
Key Clinical Considerations
Monitor and adjust for residual renal function: Approximately 40% of patients have urine output >500 mL at 24 hours post-CRRT initiation 3. In obese patients with preserved urine output, the combination of CRRT effluent plus native kidney clearance may result in excessive solute removal if dosed by actual weight.
Expect effluent rate variability in first 24 hours: QE changes >0.75 L/hour occur in 21.6% of patients during the first 24 hours of CRRT 3. Reassess dosing at 24 hours and adjust based on clinical response and metabolic parameters.
Common Pitfalls to Avoid
- Do not dose based on actual body weight - This leads to excessive treatment intensity and increased mortality risk in obese patients 1
- Do not use adjusted body weight formulas - These also correlate with worse outcomes compared to IBW 1
- Do not assume higher doses are always better - The obesity paradox shows that obese patients actually have lower 90-day mortality (55% vs 62%, p=0.02) 1, suggesting they may be more vulnerable to excessive CRRT intensity
Monitoring Parameters
Use marker clearance as the primary basis for CRRT dosing rather than absolute urea or creatinine levels, as these must be interpreted in the context of their rates of change over time 2. In obese patients, steady-state solute levels may be misleading due to altered volume of distribution.
The minimum acceptable dose remains a Kt/V of 1.2 delivered three times weekly for intermittent therapy, though continuous therapy at 35 mL/kg/hour (IBW) provides superior outcomes in critically ill patients 2.